Utilisation of the ESMO-MCBS in practice of HTA

Affiliations

¹ Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at.
² Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
³ Independent Pharmaceutical Consultant, Mellieha, Malta.
⁴ Department of Finance, University of Vienna, Austria.
⁵ Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
⁶ Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania.
⁷ Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
⁸ Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
⁹ Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania.
¹⁰ Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK.
¹¹ Agency for Health Technology Assessment and Tariff System, Warsaw, Poland.

Free article

Comment

C Wild et al. Ann Oncol. 2016 Nov.

Free article

. 2016 Nov;27(11):2134-2136.

doi: 10.1093/annonc/mdw297. Epub 2016 Aug 8.

¹ Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at.
² Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
³ Independent Pharmaceutical Consultant, Mellieha, Malta.
⁴ Department of Finance, University of Vienna, Austria.
⁵ Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
⁶ Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania.
⁷ Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
⁸ Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
⁹ Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania.
¹⁰ Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK.
¹¹ Agency for Health Technology Assessment and Tariff System, Warsaw, Poland.

No abstract available

Comment in

Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.
Cherny NI, Sullivan R, Dafni U, Bogaerts J, Kerst JM, Zielinski C, Piccart MJ, de Vries EG. Cherny NI, et al. Ann Oncol. 2016 Nov;27(11):2136-2137. doi: 10.1093/annonc/mdw406. Epub 2016 Aug 29. Ann Oncol. 2016. PMID: 27573563 No abstract available.